Get started

Geneediting

KRRO a biotech company with earnings coming LONGKRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods . A recent analyst gave it an upside to 100 which is very favorable given its product line and track record with an all-time high of about $250 ( which is about 450% over current valuation) On the one-hour time frame, it has had a great week and is breaking out over its moving averages as well as bullish momentum on the dual TF RSI indicator. This is a stock-long trade in the biotechnology sector which is prognosticated to be among the best of 2024. The dramatic reversal on the chart tells me this is a long entry. Targeting $57.5 in the short term and $75.00 for most of the position in consideration of the analyst report.
NASDAQ:KRROLong
by AwesomeAvani
1
(MGX)Metagenomi, Inc.: A Genetic Medicine Powerhouse on the RiseNASDAQ:MGX here's an analysis of Metagenomi, Inc.: Chart Data is limited.. Financial Performance: Market Cap: $456.337 million Previous Close: $12.25 52 Week Range: $9.74 - $12.74 Volume: 392,654 Avg. Volume: 1,187,350 Recent News: Introduction: In the dynamic realm of genetic medicine, where breakthroughs hold the promise of revolutionizing healthcare, one company stands out for its pioneering efforts and recent market buzz – Metagenomi, Inc. With a low share price and a scorching-hot market for gene research, investors are eyeing Metagenomi with keen interest. Let's delve into the company's profile, recent developments, and the compelling reasons why it might just be the next big investment opportunity. Company Overview: Metagenomi, Inc., headquartered in Emeryville, California, emerges as a leading player in the gene editing biotechnology sphere. Established in 2016, Metagenomi is dedicated to developing therapeutics using its proprietary metagenomics-derived genome editing toolbox. This arsenal comprises programmable nucleases, base editors, and RNA/DNA-mediated integration systems, positioning the company at the forefront of genetic medicine innovation. Recent IPO and Insider Trading: A recent initial public offering (IPO) catapulted Metagenomi into the spotlight, with 6,250,000 shares of common stock issued at a public offering price of $15.00 per share. Additionally, insider trading activity has surged, with Novo Holdings A/S, a notable insider, acquiring a significant stake of 900,000 shares at a price of $14.47 per share. This insider confidence underscores Metagenomi's potential and serves as a bullish indicator for prospective investors. Financial Performance and Market Positioning: Despite its relatively modest market capitalization of $456.337 million, Metagenomi boasts a compelling growth trajectory. Recent financial data indicates a positive momentum, with total revenue reaching $37.952 million, signaling robust demand for the company's innovative genetic therapies. Furthermore, the company's strategic collaborations with industry giants like ModernaTX, Inc. and Ionis Pharmaceuticals, Inc. underscore its market credibility and growth potential. Gene Research Revolution: Metagenomi's strategic focus on precision genetic medicines aligns perfectly with the burgeoning gene research revolution. As the healthcare landscape increasingly gravitates towards personalized therapies and gene editing technologies, Metagenomi stands poised to capitalize on this paradigm shift. The convergence of cutting-edge science, favorable regulatory tailwinds, and heightened investor interest in genetic medicine positions Metagenomi as a prime beneficiary of the gene research boom. Investment Considerations: While Metagenomi's low share price and the red-hot gene research market present compelling investment opportunities, prudent investors must weigh certain considerations. The biotechnology sector inherently entails high risk and volatility, with clinical trial outcomes, regulatory approvals, and competitive dynamics exerting significant influence on stock performance. Additionally, Metagenomi's status as an early-stage company necessitates a long-term investment horizon and a tolerance for market fluctuations. Conclusion: In conclusion, Metagenomi, Inc. emerges as a compelling investment opportunity in the genetic medicine landscape. With a low share price, recent IPO buzz, and a strategic foothold in the gene research revolution, Metagenomi embodies the quintessential blend of innovation, potential, and market positioning. While investors must exercise due diligence and navigate the inherent risks of the biotechnology sector, Metagenomi's transformative vision and burgeoning market opportunities make it a stock worth watching and potentially adding to one's investment portfolio.
NASDAQ:AMDLong
by OnePunchSolutions
1
QSI Quantum-Si Earnings Release on Monday, Before the BellIf you haven`t bought the Double Bottom: Then you should know that QSI, Quantum-Si incorporated, also known as The Protein Sequencing Company is bringing single-molecule protein sequencing to every lab, everywhere, enabling new discoveries that will transform the world we live in. Importance of Protein Sequencing: - Understanding Cellular Processes: Proteins are involved in virtually every cellular process, and their sequencing is vital for understanding how these processes are regulated and how dysfunction leads to diseases. - Drug Development: Protein sequencing assists in drug discovery by identifying specific targets for pharmaceutical intervention. This knowledge enables the design of drugs that can interact with specific proteins, thereby treating diseases more effectively. - Bioengineering and Enzyme Production: Protein sequencing is critical in the field of bioengineering, allowing the design of proteins with tailored functions for various applications, including industrial enzyme production and bioremediation. I think protein sequencing should have the same importance as gene sequencing. Gene sequencing has revolutionized medical research, agriculture, and our comprehension of evolutionary history. On the other hand, protein sequencing has paved the way for targeted drug development, bioengineering, and the investigation of cellular processes. QSI has cash and cash equivalents of $322.1 million as of March 31,2023 to provide a runway to support operations and invest in the business into 2026, and NO debt! This Quarter started he sale of PlatinumTM instruments and kits with a gross margin of 48.8%. QSI has a Market Cap of $485Mil vs CRSP, my favorite gene editing company, with a Market Cap of 4.046Bil. So there is still a lot of upside in QSI Quantum-Si incorporated! Looking forward to read your opinion about it.
NASDAQ:QSILong
by TopgOptions
BNTC Gene Therapy Penny Stock at All Time LowBNTC Benitec Biopharma Inc is a development-stage biotechnology company which focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics. BlackRock Inc., Renaissance Technologies LLC, Vanguard Group Inc. and Morgan Stanley have stakes in it. On 2/17/2022 P. Trucchio from HC Wainwright brokerage Initiated Coverage for BNTC with a Buy rating and a price target of $10.00. The price of the stock can easily double in my opinion.
NASDAQ:BNTCLong
by TopgOptions
1
AVRO 1330% upside potential according to this analyst!!!AVROBIO is a clinical-stage gene therapy company to treat rare diseases following a single dose worldwide. AVRO just released positive data on their Phase 1/2 trial testing the safety and efficacy of AVR-RD-04. 73.42% of the shares are controlled by institutional investors, which gives me a lot of trust in the company. JPMorgan Chase and BlackRock Inc. have the largest stakes in the company with an average around $9 per share. On 1/5/2022 Barclays brokerage Boosted the Price Target of AVRO from $6.00 to $22.00. The stock is now at all time low: $1.65. the MARKET CAP is only 71.978Mil I think it can be an easy buyout at this point. What are we waiting for?
ALong
by TopgOptions
2
BNTC Gene Therapy Penny StockBTC Benitec Biopharma is sitting now at a key support from which we can expect a bounce. We know that earlier this year they had a 7.5mil offering price to the public of $4.25 per share and that Morgan Stanley has a 5.2% stake in the genetic drug company. Benitec's "proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Market Cap 22.472Mil My price targets are 4.70 and 5.70 usd.
NASDAQ:BNTCLong
by TopgOptions
Crispr - DNA/Gene editing Technical Analysis Since early December, we have had over a dozen tails on the purple up-trend arrow drawn in. The 50sma is now coming into play, as a break below that, could take us another 20% down to the 100sma. An appropriate level to exit the trade then, would be below the 50sma. There also horizontal support as we fill the gap. Important Note: Earnings are on February 10th; so be aware of this if you plan to enter the trade. Opinion I believe this company is the future of gene editing. Check out a documentary of the company on Netflix called Human Nature. *It is more about how Crispr (DNA modification) works, than how the company makes money. Enjoy your weekend, dorfmaester
NASDAQ:CRSPLong
by dorfmanmaster
LINK and CRSP similar structureLINK and CRSP have very similar looking charts of a long term ascending triangle breakout that quickly occurred relative to the total length of the triangle. Both have strong fundamentals, each having their place in the 4th industrial revolution. CRSP is on a 2.2x slower timescale than LINK, so LINK may be able to foreshadow price targets on CRSP. Fib extension of denoting the triangle breakout level to be 38.2% of the projected peak, says that LINK may hit ~$10 (agreeing with the previous LINK and ETH comparison) in 2020 which would infer that CRSP could reach ~$140 by late 2020-2021.
NASDAQ:CRSPLong
by thunder_clef
1
Sangamo's: Doom or Gloom ScenarioRecent data release may have changed SGMO's future outlook. Sangamo's long-term chart suggests a potential pullback to $4 is a possibility, but that was before a recent data release by the company for updated Phase 1/2 Results for SB-525 . This is an investigational Hemophilia-A gene therapy that showed sustained increased Factor VIII Levels with no reported bleeding events and no factor usage for as long as 24 weeks of follow-up. Some traders do not believe in technical analysis, that's fine, but I think you may want to re-consider and hear me out on this one. Most didn't believe in Sangamo either (aren't I right Sangamo fan's)!! What Does The Chart Say? The long-term pattern (from day of IPO) suggests that if Sangamo Therapeutics stock price continued its trend, it was a possibility that pattern would repeat therefore potentially pulling back to December 2016 lows of around $3.67. Although this may still be a possibility, Sangamo caught wind in its sails on good data release recently, re-igniting investor optimism. I remain cautiously optimistic with Sangamo, so I went ahead and put together a short-term game plan just in case. Take a look at short list of what I will be watching for while I wait for further confirmation of long-term trend indication. When making previous highs, Sangamo's stock price has entailed devastating 5-wave corrections, however: The daily chart suggests that instead of a 5-wave correction that could potentially take SGMO to sub $4, SGMO's chart details an AB=BC corrective wave that could potentially mark the low of the long-term selloff. AB=BC corrective waves are equal in length/or magnitude and on a Bullish correction would bounce off the 0.786 retracement level. SGMO had a sharp bounce off this level in Feb 2019 and closed the day right above the 0.786 retracement zone. This is a very important level of support to close upon. If this did not happen I would be on the other side of the trade waiting for a wash, down to $4. But from my experience there still may be fighting chance. Short-term (from Feb 2019 to now) SGMO continues to make higher lows, this is #Bullish. Although SGMO looks to have failed to break current resistance in the chart above,volume/optimism packed enough punch to test $11.85 which is a 1.618 Fibonacci extension (normal extensions range from 1.272 or 1.414).. . #Bullish May not be exactly what a Long-term investor's of SGMO would want to hear, but a pullback around .618-.786 retracement (shown in green-zone on chart) would be a nice place to add for swing-trade up to earnings. Previous earnings have brought 10-20% run-ups, but be careful to not get trapped in an earnings selloff. If SGMO continues to make higher-lows, this could be a potential range to be looking for a swing position. Breakout of this zone could mean big $$ Fall below blue trend line could mean devastation my stop-loss will be set below blue trend-line. Again, it's a long way down to $4 if trend continues to follow its Long-term pattern. Previous trends have issued 5-wave correction, peak to trough, the current pattern details an AB=BC harmonic pattern (outlined in #RED) please press play and zoom out to see what I am referring to. Tip # 5 : A trend line in mathmatical terms means the line of best fit. When using them, make sure they touch as many points as possible on the chart. Please like and follow so I can continue doing technical analysis. Thank you in advance everyone =) @VolatilityWatch @scooby_snack Disclosure: I do not own SGMO. I may buy/sell within the next 72 hours. This is not a note to buy or sell. Please do your homework before investing. //---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Check out my some of my current trades.
NASDAQ:SGMO
by follow_the_money
1
Is CRSP going to "technically" break the bear trend this weekIn my previous post on #CRISPR I talked about the Green upward sloping trendline & how every time CRSPR has traded on or below it since May 2017 we've seen parabolic action. I don't want to say I told you so, but we've seen some parabolic action. To my surprise, the parabolic movement came the news of Vertex upfront payment of $175 million upfront payment. Specifically, Vertex gets worldwide rights for CRISPR/Cas9 technology along with other items such as AAV vectors for DMD and DM1. This deal totals just about $1 billion when you factor in all milestone payments for these programs, plus royalties. Moving on to the chart now.. It appears as though CRSP is about to "technically" breakout of the bear trend which started in May 2018 after reaching ATH's. The blue downward sloping trendlines are the attached to the swing highs, and one has already been broken to the upside, which could be considered the first real confirmation of a trend reversal. Once the second blue downward sloping trendline is broken to the upside CRSP is "technically" out of the bear trend, IMO. Time will tell per usual.
NASDAQ:CRSPLong
by ScotianBot